Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®

Exclusion Criteria

• •History of documented invasive meningococcal disease.
• •Received any other meningococcal vaccine
• •Received any vaccine (other than desensitization therapy for allergies) in the 28-day period prior to enrollment
• •Scheduled to receive any vaccination in the 28-day period after enrollment
• •Received systemic antibiotic therapy within the 72 hours prior to collection of a blood sample
• •Actively enrolled or scheduled to be enrolled in another clinical study
• •Serious chronic disease (i.e., cardiac, renal, neurologic, rheumatologic, metabolic, gastrointestinal, hematologic, psychiatric, or other organ system)
• •Known or suspected impairment of immunologic function
• •Acute medical illness with or without fever within 72 hours or an oral temperature ≥ 100.4°F (≥ 38.0°C) at the time of inclusion
• •Administration of immune globulin, other blood products, or corticosteroid within 3 months of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting \< 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment.
• •Personal or family history of Guillain-Barre Syndrome
• •Suspected or known hypersensitivity to any of the vaccine components
• •Unavailable for the entire study period or unable to attend the scheduled visits or to comply with the study procedures
• •Any condition, which in the opinion of the investigator would pose a health risk to the participant.